After an initial career in England and Nigeria, Dr. Kershaw has established himself in Canada as a leading plant ecologist. His approach to ecological problems is very broad, ranging from phytosociology to physiological ecology. He has concentrated on studying the lichen-dominated systems in the Arctic, particularly in North-Western Ontario, and has done notable work on the effect of fire on these systems and on gas exchange, water relations, effects of high and low temperatures and nitrogen metabolism of the important lichens. He has published more than 80 papers, has a very active research group and is recognized internationally as an outstanding plant ecologist.

Nathan Keyfitz, B.Sc. (McGill), Ph.D. (Chicago), is Senior Research Statistician in the Dominion Bureau of Statistics. It is a very special pleasure for me to introduce him to the Society since he has recently accepted an appointment as a Professor of Sociology in the Department of Political Economy in the University of Toronto. He has achieved distinction in four distinct careers: as a mathematical statistician, as a demographer, as a student of the cultures of southeast Asia, and as consultant for programmes of economic development. The University of Toronto is proud of its new Professor; this Society will be equally proud of its new Fellow.

Dr. Doreen Kimura is an international leader in human neuropsychology. Her early work at the MNI shed new light on the perceptual and memory functions of the temporal lobes. She was the first to use the Broadbent dichotic-listening technique to demonstrate a dual functional asymmetry in the auditory system and its relation to cerebral dominance for speech. At The U. of Western Ontario, in a set of ingenious experiments, she established a close link between the programming of the oral movements of speech and that of nonverbal oral and manual movements. Her present research focusses on individual differences in cerebral organization, including hormonal influences.

Professor G.W. King is a spectroscopist with an international reputation. His thesis under Ingold on the excited states of acetylene is A classic. Since then he has made many further important contributions to our knowledge of ultraviolet absorption spectra of a large number of interesting molecules, as well as to the study of their infrared and Raman spectra. In addition he has contributed to a theoretical understanding of the results. His book "Spectroscopy and Molecular Structure" is an excellent, well thought-out presentation of the subject and has been well received by students and teachers alike.

With nearly 100 research papers to his credit, John Kirkaldy's reputation as a physical metallurgist has been recognized nationally and internationally by numerous awards. As a professional engineer, he maintains active liason with industry in a consultative capacity. He also has taken a leadership role in educational matters as Chairman of the Department of Metallurgy and Materials Science at McMaster University, as President of the Ontario Confederation of University Faculty Association, and as a member of the Commission on Post-Secondary Education in Ontario. In Summary, Kirkaldy has made outstanding contributions in teaching, research, university administration and in public affairs.

Long Citation Dr. Kisilevsky's basic studies on abnormal protein folding (amyloid) have led to therapy for some of the important diseases of our time. He has designed agents and drugs to arrest and reverse this process, which are approved for the treatment of amyloidosis, and are in a FDA expedited Phase III clinical trials for the treatment of Alzheimer's disease. Similar blocking agents are used to treat malaria. Finally, the physiological function of one of these amyloid proteins in cholesterol transport have led to mechanisms to treat atherosclerosis which leads to stroke and heart attacks. Two highly successful biotechnology companies have been founded on his research. Short Citation Dr. Kisilevsky's basic studies on abnormal protein folding have led to important therapies for some of the important diseases of our time. He has designed agents and drugs, which are approved for the treatment of amyloidosis, and are in a FDA expedited Phase III clinical trials for the treatment of Alzheimer's disease. Similar blocking agents are used to treat malaria and similar protein interactions in cholesterol transport have led to treatments for atherosclerosis.